Article
CNBC
(2020)
The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly's experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech company AbCellera.
.png?locale=en "Created by CourseChunks App")
CourseChunks
updated 5 months ago
0 likes
Comments
MORE RESOURCES FROM SOURCE
More in Course Chunks from CNBC
No comments yet. Be the first to comment!